Chimeric PCV1-2b Vaccine for Cross-Protection Against PCV2b
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines based on PCV2a subtype may not provide complete protection against the globally dominant PCV2b subtype, which is associated with severe clinical porcine circovirus-associated disease (PCVAD), highlighting the need for a vaccine specifically targeting PCV2b.
Innovation Solution
Development of a live-attenuated chimeric vaccine using the PCV1-2b virus, which incorporates the capsid gene of PCV2b subtype into the genomic backbone of non-pathogenic PCV1, providing immunogenicity and cross-protection against both PCV2b and PCV2a subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines based on PCV2a subtype are used, then protection against PCV2a is achieved, but protection against PCV2b subtype is insufficient
Solution Approach 1:
The chimeric vaccine incorporates the capsid gene from PCV2b into the PCV1 backbone, creating a single vaccine that provides protection against both PCV2a and PCV2b subtypes. This multi-functional approach allows the vaccine to address multiple viral subtypes simultaneously, resolving the contradiction between protection efficacy and subtype coverage.
Solution Approach 2:
The vaccine uses a composite viral structure combining genetic elements from two different PCV subtypes (PCV1 backbone and PCV2b capsid). This composite approach creates a vaccine that exhibits properties of both parent viruses, enabling broad protection against multiple subtypes while maintaining safety.
2Reliability
If a vaccine specifically targeting PCV2b is developed, then protection against PCV2b is improved, but cross-protection against PCV2a may be reduced
Solution Approach 1:
The chimeric vaccine design ensures that the PCV2b-specific capsid antigen is presented on a PCV1 backbone that has demonstrated safety and immunogenicity. This structure enables the vaccine to elicit strong type-specific immunity against PCV2b while the PCV1 framework maintains cross-reactive immune responses against PCV2a, achieving both specialized and broad protection.
3Reliability
If a live-attenuated chimeric vaccine is used, then immunogenicity and cross-protection are enhanced, but virus pathogenicity must be controlled
Solution Approach 1:
The vaccine applies local quality modification by introducing only the specific capsid gene region from PCV2b into the PCV1 genome, while leaving the rest of the viral genome (including attenuation determinants) unchanged. This localized genetic modification ensures that the vaccine maintains the safe, attenuated properties of PCV1 while gaining the immunogenic advantages of PCV2b capsid antigens.
Solution Approach 2:
The PCV1 viral backbone acts as an intermediary carrier that delivers the PCV2b capsid antigen safely to the host. The PCV1 framework mediates between the need for strong immunogenicity (provided by PCV2b) and the need for safety (provided by PCV1's attenuated nature), enabling the chimeric virus to function as an effective and safe live-attenuated vaccine.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD).